Amycretin Tracker App for Side Effects, Food, and Weight
MeAgain is an Amycretin tracker for the record you can build now: current medication, side effects, food, water, and weight trend. Amycretin, also called zenagamtide, is a Novo Nordisk drug in testing that uses one molecule to work on two hunger signals. Novo is studying both a weekly shot and a daily pill version. As of July 2026, Amycretin is not FDA-approved and is not available to the public. The best-known obesity result is 24.3% average weight loss at 36 weeks in an early-phase Lancet-published study with 125 participants, and the larger Phase 3 AMAZE 1 study started in February 2026 with completion listed in 2029. That means availability is years away. MeAgain helps you track what matters while waiting or in a study: current medication, side effects, food, water, and the long weight trend. Your history carries over if new medications arrive later. 421K users already use MeAgain, with 4.8 stars across 21K App Store ratings.
Key takeaways
Amycretin - Novo Nordisk has also started calling it zenagamtide - is a single molecule that works on two hunger signals at once, and it is being studied in two forms: a weekly shot and a daily pill.
Amycretin has no FDA approval and no public availability as of July 2026. AMAZE 1, the Phase 3 obesity study, began in February 2026 and is not expected to finish until 2029 - a long runway.
The 24.3% weight-loss result comes from an early-phase, Lancet-published obesity study with 125 participants over 36 weeks. It is attention-grabbing, but it is not the same as completed Phase 3 evidence or approval.
Novo is also testing a daily pill version of Amycretin. The early oral study reported about 13.1% weight loss over 12 weeks, a short trial window that should not be treated as a public dosing guide.
MeAgain is useful now because the tracking habit does not have to wait for approval. Track your current medication, side effects, food, water, and weight trend; if new medications arrive later, that history carries over.
What Makes MeAgain the Right Amycretin Tracker?
01A Tracker for the Weekly Shot and Daily Pill Possibilities
Amycretin is unusual because Novo is testing it in two forms at once: a weekly shot and a daily pill. MeAgain can support the practical record around either kind of routine without turning trial details into user instructions. If you are following the research, you can track your current medication, side effects, meals, water, and weight trend now. If you are in a study, you can keep a cleaner day-by-day record while following the study team's instructions. If Amycretin reaches the public years from now, your MeAgain history still carries forward, giving you a useful before-and-after timeline instead of disconnected notes. The same record also helps if your medication changes before Amycretin is available because the baseline is already built in one place today.
02Side Effect Notes That Stay Connected to Food and Weight
Novo's Amycretin updates describe side effects mostly as stomach and digestion issues, including nausea, vomiting, lower appetite, diarrhea, and constipation. Those symptoms are easier to understand when they are logged next to meals, water, current medication, and weight. MeAgain keeps that record in one place. You can add common symptoms, create custom notes, and review the timeline later instead of trying to remember which day felt rough. That is useful while waiting on Phase 3 results because the tracking routine is not Amycretin-specific. It is the same practical habit people need with current GLP-1 medications and future ones. A consistent symptom record also makes it easier to discuss patterns with a clinician across several weeks, not just one rough day.
03Weight Trends Built for a Long Research Timeline
The Amycretin result people quote most often is 24.3% average weight loss at 36 weeks, but that came from an early-phase study with 125 participants. The larger Phase 3 obesity study started in February 2026 and lists completion in 2029. That long gap is exactly why a tracker should focus on the record you can build now. MeAgain's weight chart helps daily or weekly swings sit inside a longer trend, while food, water, and symptom logs explain the context around that trend. If a future medication changes your routine, the earlier history still helps you understand what actually changed. The chart makes the wait measurable without turning every weigh-in into a verdict.
04A Current-Med History That Does Not Reset Later
Waiting for Amycretin does not mean waiting to track. If you are using semaglutide, tirzepatide, or another medication today, MeAgain can already hold the core record: current medication, side effects, food, water, and weight trend. That matters because new medications rarely arrive into a blank life. They arrive after months or years of habits, symptoms, food patterns, and weight changes. MeAgain keeps that history together so future changes are easier to understand. If Amycretin later becomes relevant to your care, you can compare the new routine with the record you already built. That makes the app useful during the research years, not only after a launch.
What to Know About Amycretin Availability and Tracking
As of July 2026, Amycretin, also called zenagamtide, is experimental, in clinical trials, and not FDA-approved. Novo is studying one molecule that works on two hunger signals, with both weekly shot and daily pill forms in development. The most-cited obesity number - 24.3% average weight loss at 36 weeks - comes from an early-phase study of 125 people published in The Lancet, which is promising but not the same as completed Phase 3 evidence. The larger AMAZE 1 obesity study started on February 24, 2026, with primary completion listed for June 26, 2029 and study completion for August 21, 2029. That means availability is years away. MeAgain gives you the tracker for the part you can use now: current medication, side effects, food, water, and the long weight trend.
| Amycretin | Tirzepatide / Zepbound | Semaglutide / Wegovy | |
|---|---|---|---|
| Current U.S. status | Trial-only, not FDA-approved | FDA-approved | FDA-approved |
| Forms discussed on this page | Weekly shot and daily pill versions in testing | Weekly shot | Weekly shot |
| Sourced trial weight results | 24.3% in 36 weeks (early-phase Lancet study, n=125) | 20.9% in 72 weeks (SURMOUNT-1) | 14.9% in 68 weeks (STEP-1) |
| Evidence stage | AMAZE 1 began February 2026; completion listed in 2029 | Approved drug with published Phase 3 obesity data | Approved drug with published Phase 3 obesity data |
| What MeAgain helps you track | Current med, side effects, food, weight trend | Current med, side effects, food, weight trend | Current med, side effects, food, weight trend |
Amycretin Facts to Know Right Now
- As of July 2026, Amycretin remains trial-only and has no public availability
- Amycretin is also called zenagamtide in newer Novo Nordisk materials
- It is one molecule being studied to work on two hunger signals
- Novo is studying both a weekly shot version and a daily pill version
- The early-phase obesity study reported 24.3% average weight loss at 36 weeks in 125 participants
- The early oral study reported about 13.1% weight loss over 12 weeks
- AMAZE 1 started February 24, 2026, with completion listed in 2029
- The tracker basics stay simple: current medication, side effects, food, water, and weight trend
Amycretin availability is years away, but the tracking habit is useful today. MeAgain keeps your current medication, side effects, food, water, and weight trend in one place so the record is ready if your medication changes later.
This content is for informational purposes only and does not constitute medical advice. As of July 2026, Amycretin is experimental, in clinical trials, and not FDA-approved for any use. Published Amycretin results may change as more Phase 3 data are released. Always talk with a licensed clinician about Amycretin, weekly GLP-1 treatment, or weight-management medication. MeAgain is not affiliated with Novo Nordisk and does not enroll people in Amycretin trials.
Sources
- The Lancet - Amycretin early-phase weekly shot and daily pill data
- PRNewswire - Amycretin advanced to Phase 3 after Lancet publication
- ClinicalTrials.gov - AMAZE 1 Phase 3 obesity trial
- Novo Nordisk - Phase 2 Amycretin type 2 diabetes results (November 25, 2025)
- Jastreboff AM et al. - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539)
- Wilding JPH et al. - Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1, NEJM 2021, n=1,961)
What MeAgain Users Track Before New Meds Arrive
Why People Use MeAgain While Amycretin Is Still Trial-Only
As of July 2026, Amycretin is not publicly available, so there are no Amycretin-specific App Store reviews. The tracking pattern it would need already exists in how people use the app on today's medications. One reviewer starting out (JLO23, July 1, 2026) described it:
I like the ease of use and the gentle reminders. Easy to keep track of your shot day and track any symptoms each day.
Whether Amycretin eventually arrives as a weekly shot or a daily pill, that is the same record - doses, symptoms, food, water, weight - and it is what people following the research or taking part in a study track right now.
MeAgain keeps the record focused on what can be tracked today: current medication, side effects, meals, water, and weight trend. For anyone waiting on Amycretin news, that means the tracking habit does not depend on a launch timeline. If your medication changes later, the history you already built still gives you a clearer before-and-after view.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Learn More About Amycretin, Side Effects, and Weekly Shot Tracking
What Orforglipron Phase 3 Results Mean for Oral GLP-1s
Orforglipron Phase 3 results explained—what they mean for oral GLP-1 development, efficacy, safety, and future treatment options.
Amycretin Tracker - FAQs
Amycretin is Novo Nordisk's experimental weight-management drug, renamed zenagamtide in the company's newer materials. A single molecule built to act on two hunger signals, it is being tested as a weekly shot and as a daily pill - and as of July 2026 it has no FDA approval and no public availability. The Phase 3 obesity study AMAZE 1 started in February 2026 and lists completion in 2029, so availability is years away. The practical answer is to track what you can use now: current medication, side effects, meals, water, and weight trend. MeAgain keeps that history together so it can carry forward if Amycretin or another new medication becomes part of your care later.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.